Advertisement
UK markets open in 2 hours 50 minutes

  • NIKKEI 225

    37,686.72
    -773.36 (-2.01%)
     

  • HANG SENG

    17,283.28
    +82.01 (+0.48%)
     

  • CRUDE OIL

    82.89
    +0.08 (+0.10%)
     

  • GOLD FUTURES

    2,325.60
    -12.80 (-0.55%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,498.16
    -1,969.84 (-3.68%)
     

  • CMC Crypto 200

    1,390.36
    -33.74 (-2.37%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Integumen PLC: Unveiling of new breath test/dig'l health platform

Integumen PLC
·2-min read

Unveiling of new COVID-19 personalised real-time Breath Test and Digital Health Pass Platform

COVID-19 wastewater Microtox ready for beta testing

Heads of Agreement with Avacta and Aptamer Group for commercial scale supply of SARS-CoV-2 binding agents

YORK, England, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Integumen today announces progress for its COVID-19 wastewater detection system, Microtox PD, in collaboration with Modern Water plc ("Modern Water"), Avacta Group plc ("Avacta") and Aptamer Group Limited ("Aptamer"). The Company also today announces the unveiling of a new personalised COVID-19 breath test, Microtox BT, and its complementary Digital Health Pass platform.

ADVERTISEMENT

Integumen is working with a consortium of companies collaborating to find solutions in the fight against COVID-19 pandemic. The consortium includes Modern Water, Avacta, Aptamer and a major global provider of innovative technology and services for the data era.

Microtox BT and Digital Health Pass - on the spot triaging of COVID-19 infections offer potential to re-open the economy
Integumen recognised that in collaboration with Modern Water, Avacta and Aptamer Group, its real-time detection and alert system could be adapted to detect the level of infection of coronavirus in a breath sample. Adapting the wastewater test, Microtox PD, the Company has designed, built and tested a prototype, Microtox BT, which can analyse the breath and detect the spike protein of SARS-CoV-2 in real-time for those with a high viral load. Microtox BT has undergone extensive internal testing and will now transition to the University of Aberdeen containment level 3 laboratory, to undergo tests directly on the virus followed by a joint trial of up to 5,000 participants in parallel with third parties using reverse transcription polymerase chain reaction ("rtPCR")[i] and Antigen tests. Results are anticipated before the end of the year and Microtox BT is expected to be a Class 1 medical device[ii].

Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/9879Z_1-2020-9-24.pdf

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

AIM share code: SKIN